ADC Therapeutics (ADCT) Cash from Operations Growth (1y) (2021 - 2026)
ADC Therapeutics (ADCT) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | ADC Therapeutics | 174.95 Mn | -56.06 Mn | 17.38 Mn | 47.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47.26% |
| Dec 31, 2025 | -42.43% |
| Sep 30, 2025 | -18.32% |
| Jun 30, 2025 | 26.66% |
| Mar 31, 2025 | -27.76% |
| Dec 31, 2024 | 30.92% |
| Sep 30, 2024 | 31.71% |
| Jun 30, 2024 | 6.12% |
| Mar 31, 2024 | -186.48% |
| Dec 31, 2023 | 41.00% |
| Sep 30, 2023 | -1,770.75% |
| Jun 30, 2023 | 34.00% |
| Mar 31, 2023 | 54.57% |
| Dec 31, 2022 | 13.01% |
| Sep 30, 2022 | 103.75% |
| Jun 30, 2022 | 8.62% |
| Mar 31, 2022 | 38.56% |
| Dec 31, 2021 | -19.22% |
| Sep 30, 2021 | -34.08% |
| Jun 30, 2021 | -41.93% |